Lacosamide Accord

Lacosamide, the active ingredient in Lacosamide Accord, is an anticonvulsant presented as an injectable solution for intravenous use. It is employed as adjunctive therapy to control partial‑onset seizures in patients with epilepsy, offering a rapid onset of action in acute settings.

GNH USA supplies Lacosamide Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution.

Lacosamide is an anticonvulsant that acts on neuronal sodium channels to manage seizure disorders.

Partial‑onset seizures: reduces seizure frequency as adjunctive therapy in epilepsy patients. Focal epilepsy: provides additional seizure control when other antiepileptics are insufficient. Refractory epilepsy: offers an alternative option for patients not responding to standard treatments.

Lacosamide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness - Headache - Nausea - Fatigue

Serious or Rare Side Effects: - PR‑interval prolongation leading to cardiac arrhythmia - Severe skin reactions such as Stevens‑Johnson syndrome - Suicidal ideation or behavior

When using Lacosamide, several precautions should be observed to ensure safe administration.

Cardiac monitoring: assess baseline ECG and monitor for PR interval prolongation. Renal impairment: adjust dose in patients with severe renal dysfunction. Pregnancy: use only if benefit outweighs risk; classified as Category B. Abrupt discontinuation: taper dose to avoid seizure worsening. Drug interactions: review concomitant medications that affect sodium channels or CYP3A4. Store at room temperature: keep in original packaging, protect from moisture.

Lacosamide can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Concurrent use with other sodium‑channel blockers (e.g., carbamazepine, phenytoin) may increase risk of cardiac conduction abnormalities. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can raise lacosamide plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine) may reduce lacosamide levels, diminishing effectiveness.

Moderate Interactions (Monitor Closely): - Alcohol or other CNS depressants: may enhance sedation and dizziness. - Diuretics that cause electrolyte imbalance: monitor for hyponatremia. - Selective serotonin reuptake inhibitors (SSRIs): may increase risk of dizziness.